A retrospective analysis in C57BL6/J mice used in dietary carcinogenicity studies was performed to determine the survival rate, causes of death and incidences of spontaneous non-tumoral and tumoral findings. Data were collected from 1600 mice from control dose groups of sixteen 18-month carcinogenicity assays performed between 2003 and 2021 at the same test facility with similar environmental conditions and experimental procedures. The survival rate was high in both sexes (81%-85%) and the causes of humane euthanasia or death were mainly non-tumoral (chronic ulcerative dermatitis, atrial thrombosis). Benign tumors were more frequent than malignant tumors and females were more affected than males. Pituitary gland adenoma in females, lymphoma, bronchioloalveolar adenoma, and harderian gland adenoma in both sexes were the most common tumors. Systemic amyloidosis, the most frequent non-tumoral lesion, was observed variably across studies without sex predilection. The analysis by cohort (3 time periods of 6 years) showed a tendency toward higher incidences of lymphoma and pituitary gland adenoma and lower incidences of amyloidosis over time. The results presented here provide for the first time a robust set of control historical data in untreated C57BL/6J mice kept for 18 months contributing to build in depth knowledge of this animal model.
In December 2021, the United States Food and Drug Administration (FDA) issued the final guidance for industry titled Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers . The stated purpose of the FDA guidance is to provide information to sponsors, applicants, and nonclinical laboratory personnel regarding the management and conduct of histopathology peer review as part of nonclinical toxicology studies conducted in compliance with good laboratory practice (GLP) regulations. On behalf of and in collaboration with global societies of toxicologic pathology and the Society of Quality Assurance, the Scientific and Regulatory Policy Committee (SRPC) of the Society of Toxicologic Pathology (STP) initiated a review of this FDA guidance. The STP has previously published multiple papers related to the scientific conduct of a pathology peer review of nonclinical toxicology studies and appropriate documentation practices. The objectives of this review are to provide an in-depth analysis and summary interpretation of the FDA recommendations and share considerations for the conduct of pathology peer review in nonclinical toxicology studies that claim compliance to GLP regulations. In general, this working group is in agreement with the recommendations from the FDA guidance that has added clear expectations for pathology peer review preparation, conduct, and documentation.
5 August 2008 in Experimental and Toxicologic Pathology
4-Hydroxyphenylpyruvate dioxygenase inhibitors (HPPDi) are mainly used as herbicides and for therapeutic use in genetic diseases of tyrosine catabolism. Their primary mechanism of action is the inhibition of the second enzyme of tyrosine catabolism, leading to an accumulation of this amino acid in blood and tissues. In this work, rats were administered diets with 1 ppm, 2 ppm, and 10 ppm of HPPD-inhibitor BCS-CR75391 for up to 28 days, and tyrosine levels were measured in blood and in selected organs using mass spectrometry combined with gas or liquid chromatography and analyzed spatially using mass spectrometry imaging (MSI). The highest tyrosine accumulation was recorded in the pancreas, followed by the eyes and the thyroid gland. Metabolomic profiling showed that other amino acids and metabolites of the citric acid cycle were influenced by the treatment. A metabolic adaptation was observed in the liver and kidney 28 days after the treatment, but not in other tissues analyzed. MSI of the thyroid gland seems to reveal an uneven accumulation of tyrosine in the tissue of rats following treatment with BCS-CR75391. Most interestingly, a significant accumulation of iodide was detected in the thyroid gland of all rats treated with the 4-hydroxyphenylpyruvate dioxygenase inhibitor. In addition, induced high tyrosine levels by a tyrosine-rich diet also provoke the accumulation of iodide in the thyroid gland. While the toxicological impact of these results needs to be further investigated, these results support the use of MSI as an innovative and powerful tool to support toxicological assessment.